Literature DB >> 30734082

Peri-operative, intravenous clindamycin may improve the resolution rate of hypertension after Roux-en-Y gastric bypass in morbidly obese patients.

Jacob J Patz1, Melissa C Helm1, Rana M Higgins1, Matthew I Goldblatt1, Jon C Gould1, Tammy L Kindel2.   

Abstract

BACKGROUND: Recent studies have suggested that potential aberrant alterations in the gastrointestinal microbiome contribute to the development of cardiovascular disease, specifically hypertension. Bariatric surgery produces significant sustained weight loss and hypertension resolution likely through multiple mechanisms which includes beneficial changes in the gut microbiome. We hypothesized that the type of prophylactic antibiotic given for bariatric surgery could impact the resolution rate of hypertension by altering the post-operative gastrointestinal microflora.
METHODS: A retrospective analysis of adult bariatric patients who underwent Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG) between 2012 and 2016 was conducted. The standard antibiotic prophylaxis was cefazolin, or clindamycin in patients with a penicillin allergy. Univariate analyses were performed comparing the differing peri-operative antibiotic treatments with resolution of hypertension at 2-week (± 1 week), 6-week (± 2 weeks), 3-month (± 2 weeks), 6-month (± 6 weeks), and 1-year (± 2 months) follow-up appointments. The criterion for resolution of hypertension was no longer requiring medication at time of follow-up.
RESULTS: In total, 123 RYGB and 88 SG patients were included. No significant differences were found between cefazolin and clindamycin regarding hypertension resolution rates after SG. However, patients who underwent RYGB and received clindamycin had a significantly higher rate of hypertension resolution compared to cefazolin. This effect started at 2 weeks post-operatively (52.4% vs. 23.5% respectively, p = 0.008) and persisted up to the 1-year (57.9% vs. 44.0% respectively, p = 0.05).
CONCLUSION: Prophylactic peri-operative, intravenous clindamycin was associated with significantly increased resolution of post-operative hypertension compared to cefazolin. This finding was not observed in SG patients. Future studies are needed to confirm the mechanism of action for this novel finding is due to the differing modifications of the gastrointestinal microflora after RYGB resulting from the specific peri-operative antibiotic administered.

Entities:  

Keywords:  Antibiotic; Gastric bypass; Hypertension; Microbiome; Sleeve gastrectomy

Mesh:

Substances:

Year:  2019        PMID: 30734082     DOI: 10.1007/s00464-019-06687-0

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  25 in total

1.  Gut dysbiosis is linked to hypertension.

Authors:  Tao Yang; Monica M Santisteban; Vermali Rodriguez; Eric Li; Niousha Ahmari; Jessica Marulanda Carvajal; Mojgan Zadeh; Minghao Gong; Yanfei Qi; Jasenka Zubcevic; Bikash Sahay; Carl J Pepine; Mohan K Raizada; Mansour Mohamadzadeh
Journal:  Hypertension       Date:  2015-04-13       Impact factor: 10.190

Review 2.  Effect of probiotics on blood pressure: a systematic review and meta-analysis of randomized, controlled trials.

Authors:  Saman Khalesi; Jing Sun; Nicholas Buys; Rohan Jayasinghe
Journal:  Hypertension       Date:  2014-07-21       Impact factor: 10.190

3.  A novel SCFA receptor, the microbiota, and blood pressure regulation.

Authors:  Jennifer Pluznick
Journal:  Gut Microbes       Date:  2013-12-20

Review 4.  Minireview: Gut microbiota: the neglected endocrine organ.

Authors:  Gerard Clarke; Roman M Stilling; Paul J Kennedy; Catherine Stanton; John F Cryan; Timothy G Dinan
Journal:  Mol Endocrinol       Date:  2014-06-03

Review 5.  Management of hypertension in CKD: beyond the guidelines.

Authors:  Eric Judd; David A Calhoun
Journal:  Adv Chronic Kidney Dis       Date:  2015-03       Impact factor: 3.620

6.  Gut microbiota after Roux-en-Y gastric bypass and sleeve gastrectomy in a diabetic rat model: Increased diversity and associations of discriminant genera with metabolic changes.

Authors:  Yan Guo; Chao-Qian Liu; Cheng-Xiang Shan; Yue Chen; Hui-Hua Li; Zhi-Ping Huang; Da-Jin Zou
Journal:  Diabetes Metab Res Rev       Date:  2016-11-08       Impact factor: 4.876

7.  Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss: links with metabolic and low-grade inflammation markers.

Authors:  Jean-Pierre Furet; Ling-Chun Kong; Julien Tap; Christine Poitou; Arnaud Basdevant; Jean-Luc Bouillot; Denis Mariat; Gérard Corthier; Joël Doré; Corneliu Henegar; Salwa Rizkalla; Karine Clément
Journal:  Diabetes       Date:  2010-09-28       Impact factor: 9.461

8.  Effect of clindamycin prophylaxis on the colonic microflora in patients undergoing colorectal surgery.

Authors:  L Kager; L Liljeqvist; A S Malmborg; C E Nord
Journal:  Antimicrob Agents Chemother       Date:  1981-12       Impact factor: 5.191

9.  Distinct patterns in the gut microbiota after surgical or medical therapy in obese patients.

Authors:  Daniel A Medina; Juan P Pedreros; Dannae Turiel; Nicolas Quezada; Fernando Pimentel; Alex Escalona; Daniel Garrido
Journal:  PeerJ       Date:  2017-06-20       Impact factor: 2.984

10.  Roux-en-Y Gastric Bypass and Vertical Banded Gastroplasty Induce Long-Term Changes on the Human Gut Microbiome Contributing to Fat Mass Regulation.

Authors:  Valentina Tremaroli; Fredrik Karlsson; Malin Werling; Marcus Ståhlman; Petia Kovatcheva-Datchary; Torsten Olbers; Lars Fändriks; Carel W le Roux; Jens Nielsen; Fredrik Bäckhed
Journal:  Cell Metab       Date:  2015-08-04       Impact factor: 27.287

View more
  2 in total

1.  A single, peri-operative antibiotic can persistently alter the post-operative gut microbiome after Roux-en-Y gastric bypass.

Authors:  Deemantha G Fernando; Fatima L Saravia; Samantha N Atkinson; Matthew Barron; John R Kirby; Tammy L Kindel
Journal:  Surg Endosc       Date:  2022-06-29       Impact factor: 3.453

2.  Effects of Antibiotics on Weight in Obese Patients after Sleeve Gastrectomy.

Authors:  Yisen Hou; Xinzhe Zhai; Xiaotao Wang; Yi Wu; Zhigan Lv; Peng Ma; Rui Yang; Haoliang Zhao; Jianli Han
Journal:  Oxid Med Cell Longev       Date:  2022-09-19       Impact factor: 7.310

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.